Álvarez-Torres, M.d.M.; Balaña, C.; Fuster-García, E.; Puig, J.; García-Gómez, J.M.
Unlocking Bevacizumab’s Potential: rCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients. Cancers 2024, 16, 161.
https://doi.org/10.3390/cancers16010161
AMA Style
Álvarez-Torres MdM, Balaña C, Fuster-García E, Puig J, García-Gómez JM.
Unlocking Bevacizumab’s Potential: rCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients. Cancers. 2024; 16(1):161.
https://doi.org/10.3390/cancers16010161
Chicago/Turabian Style
Álvarez-Torres, María del Mar, Carmen Balaña, Elies Fuster-García, Josep Puig, and Juan Miguel García-Gómez.
2024. "Unlocking Bevacizumab’s Potential: rCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients" Cancers 16, no. 1: 161.
https://doi.org/10.3390/cancers16010161
APA Style
Álvarez-Torres, M. d. M., Balaña, C., Fuster-García, E., Puig, J., & García-Gómez, J. M.
(2024). Unlocking Bevacizumab’s Potential: rCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients. Cancers, 16(1), 161.
https://doi.org/10.3390/cancers16010161